Rhealba® Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators

Abstract

Owing to their high content of flavonoids and saponins, plantlets of Avena sativa L. (Poaceae) are likely to possess anti-inflammatory and immunoregulatory properties of value in the treatment of atopic dermatitis (AD). With a view to its potential use in atopic subjects at risk of developing sensitisation to dietary proteins, we prepared a plantlet extract without proteins and isolated 2 flavonoids, isoorientin-2′′-O-arabinoside (1) and isovitexin-2′′-O-arabinoside (2), and two saponins, avenacosides A (3) and B (4). The absence of protein in this extract was evidenced by electrophoresis and Western immunoblotting. Furthermore, Western immunoblotting demonstrated the absence of cross-reaction between grain and plantlet proteins. We evaluated the anti-inflammatory activity of the plantlet extract and its compounds in vitro in a model of keratinocyte inflammation: 6-keto prostaglandin F1α production was inhibited by the plantlet extract (− 35 % and − 57 % at 10 and 30 µg/mL, respectively; p < 0.001) and isoorientin-2′′-O-arabinoside (− 31 %, − 51 %, and − 56 % at 3, 10, and 30 µg/mL, respectively; p < 0.001). Intracellular interleukin-2 production in activated T lymphocytes was also inhibited by 16 %, 27 %, and 31 % with 3, 10, and 30 µg/mL plantlet extract, respectively, and by 23 % and 32 % with 3 and 10 µg/mL avenacoside A, respectively, (p < 0.001), demonstrating their immunoregulatory activity in vitro. The plantlet extract was also effective on the phenotype and function of dendritic cells (DC) differentiated from monocytes. It decreased the expression of major histocompatibility complex class II molecules on DC and significantly impaired their stimulatory activity on autologous T‐cell proliferation (−25 %, p < 0.05). In conclusion, this protein-free oat plantlet extract exhibits anti-inflammatory and immunoregulatory activities in vitro.

Key words

Avena sativa L. - Poaceae - oat plantlet - atopic dermatitis - inflammation - immune response

References

• 1 European Medicines Agency .Evaluation of Medicines for Human Use. Assessment report on Avena sativa L., Herba and Avena sativa L., Fructus. EMEA/HMPC/202967/2007; 2008. Available at. http://www.emea.europa.eu/pdfs/human/hmpc/avena_fructus/20296707en.pdf Accessed July 28, 2010
• 2 Blumenthal M, Goldberg A, Brinkmann J. Herbal Medicine: Expanded Commission E Monographs. Austin; American Botanical Council; Boston (MA): Integrative Medicine Communications 2000
• 3 Volak J, Stodola J. [Plantes médicinales. 256 illustrations en couleurs]. Paris; Gründ 1983: 90
• 4 European Medicines Agency .Evaluation of Medicines for Human Use. Community herbal monograph on Avena sativa L., herba. EMEA/HMPC/202966/2007; 2008. Available at. http://www.emea.europa.eu/pdfs/human/hmpc/avena_herba/20296607enfin.pdf Accessed July 28, 2010
• 5 Popovici G, Weissenboeck G, Bouillant M L, Dellamonica G, Chopin J. Isolation and characterization of flavonoids from Avena sativa L.  Z Pflanzenphysiol. 1977;  85 103-115
• 6 Chopin J, Dellamonica G, Bouillant M L, Besset A, Popovici G, Weissenböck G. C-Glycosylflavones from Avena sativa.  Phytochemistry. 1977;  16 2041-2043
• 7 Wenzig E, Kunert O, Ferreira D, Schmid M, Schühly W, Bauer R, Bauer R, Hiermann A. Flavonolignans from Avena sativa.  J Nat Prod. 2005;  68 289-292
• 8 Osbourn A E. Preformed antimicrobial compounds and plant defense against fungal attack.  Plant Cell. 1996;  8 1821-1831
• 9 Middleton Jr E. Effect of plant flavonoids on immune and inflammatory cell function.  Adv Exp Med Biol. 1998;  439 175-182
• 10 Bieber T. Atopic dermatitis.  N Engl J Med. 2008;  358 1483-1494
• 11 Novak N, Bieber T, Leung D Y. Immune mechanisms leading to atopic dermatitis.  J Allergy Clin Immunol. 2003;  112 S128-S139
• 12 Mimaki Y, Nakamura Y, Nikaido T, Ohmoto T. Steroidal saponins from the bulbs of Triteleia lacteal and their inhibitory activity on cyclic AMP phosphodiesterase.  Phytochemistry. 1995;  38 1279-1286
• 13 Borenfreund E, Puerner J A. Toxicity determined in vitro by morphological alterations and neutral red absorption.  Toxicol Lett. 1985;  24 119-124
• 14 Akagawa K S, Takasuka N, Nozaki Y, Komuro I, Azuma M, Ueda M, Naito M, Takahashi K. Generation of CD1 + RelB + dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes.  Blood. 1996;  88 4029-4039
• 15 Kraft S, Wessendorf J H, Hanau D, Bieber T. Regulation of the high affinity receptor for IgE on human epidermal Langerhans cells.  J Immunol. 1998;  161 1000-1006
• 16 Tschesche R, Tauscher M, Fehlhaber H W, Wulff G. Avenacosid A, ein bisdesmosidisches Steroidsaponin aus Avena sativa.  Chem Ber. 1969;  102 2072-2082
• 17 Tschesche R, Lauven P. Avenacosid B, ein zweites bisdesmosidisches Steroidsaponin aus Avena sativa.  Chem Ber. 1971;  104 3549-3555
• 18 Aries M, Vaissiere C, Charveron M, Castex-Rizzi N. Avena sativa aerial part extract regulates skin immunoinflammatory disorders as atopic dermatitis pathology. 39th Annual Meeting of the European Society of Dermatological Research (ESDR), 10 September 2009, Budapest, Hungary.  J Invest Dermatol. 2009;  129 (Suppl. 2) S4 (Abstract 020)
• 19 Ziegler-Heitbrock H W, Ulevitch R J. CD14: cell surface receptor and differentiation marker.  Immunol Today. 1993;  14 121-125